The timing of these two new patents, just prior to forthcoming data results, is perfect.
"The first allowance bears relevance to claims involving the intravenous dosing schedule of PTX-200, including a method for identifying and treating patients with tumors in the pancreas, ovary or colon that have highly expressed Akt.
The second allowance has allowed claims bearing particular relevance to Prescient’s ongoing breast cancer clinical trial, involving the use of PTX-200 with taxanes." (4/8/16 Proactive Investors).
That is, with both the clinical trials to end before Xmas this year in their respective phase 1b, it's great to have approved patent privileges not only for commencement into phase 2 trails but most importantly a pre-requisite seen by most deals made.
Luck to us that hold.
- Forums
- ASX - By Stock
- PTX
- Ann: USPTO Grants Allowances for Two PTX-200 Patents-PTX.AX
Ann: USPTO Grants Allowances for Two PTX-200 Patents-PTX.AX, page-4
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PTX (ASX) to my watchlist
|
|||||
Last
4.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $36.23M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 7000 | 4.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.5¢ | 425311 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 7000 | 0.044 |
2 | 68723 | 0.043 |
3 | 320988 | 0.042 |
6 | 524890 | 0.041 |
7 | 643294 | 0.040 |
Price($) | Vol. | No. |
---|---|---|
0.045 | 425311 | 7 |
0.046 | 98002 | 1 |
0.047 | 613389 | 3 |
0.048 | 200000 | 1 |
0.050 | 66739 | 3 |
Last trade - 10.47am 25/07/2024 (20 minute delay) ? |
Featured News
PTX (ASX) Chart |
Day chart unavailable
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online